Truist Financial Sticks to Their Buy Rating for Insulet (PODD)
Truist Financial analyst Richard Newitter reiterated a Buy rating on Insulet today and set a price target of $360.00.
President's Day Sale - 70% Off
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
According to TipRanks, Newitter is a 5-star analyst with an average return of 10.0% and a 49.59% success rate. Newitter covers the Healthcare sector, focusing on stocks such as Inspire Medical Systems, Medtronic, and Boston Scientific.
In addition to Truist Financial, Insulet also received a Buy from Citi’s Joanne Wuensch in a report issued today. However, on the same day, TipRanks – Anthropic reiterated a Hold rating on Insulet (NASDAQ: PODD).
Based on Insulet’s latest earnings release for the quarter ending September 30, the company reported a quarterly revenue of $706.3 million and a net profit of $87.6 million. In comparison, last year the company earned a revenue of $543.9 million and had a net profit of $77.5 million
Based on the recent corporate insider activity of 64 insiders, corporate insider sentiment is neutral on the stock. Most recently, in December 2025, Frederick Wayne A.I. , a Director at PODD sold 1,851.00 shares for a total of $542,509.59.
Read More on PODD:
